Latest Articles
“Unprecedented OS Benefit” Seen in Advanced, Recurrent Endometrial Cancer - Oncology News Central
“Unprecedented OS Benefit” Seen in Advanced, Recurrent Endometrial Cancer Oncology News Central
Published: March 17, 2024, 7 a.m.
Trastuzumab Deruxtecan Proves Active in HER2-Expressing Gynecologic Cancers - Cancer Therapy Advisor
Trastuzumab Deruxtecan Proves Active in HER2-Expressing Gynecologic Cancers Cancer Therapy Advisor
Published: March 17, 2024, 7 a.m.
RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer - EurekAlert
RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer EurekAlert
Published: March 16, 2024, 7 a.m.
Research reveals link between environmental pollutants and endometrial cancer - News-Medical.Net
Research reveals link between environmental pollutants and endometrial cancer News-Medical.Net
Published: March 14, 2024, 7 a.m.
Dostarlimab given NICE go-ahead in first-line combination treatment for endometrial cancer - Hospital Healthcare
Dostarlimab given NICE go-ahead in first-line combination treatment for endometrial cancer Hospital Healthcare
Published: March 14, 2024, 7 a.m.
Melatonin: Current evidence on protective and therapeutic roles in gynecological diseases.
Melatonin, a potent antioxidant and free radical scavenger, has been demonstrated to be effective in gynecological conditions and female reproductive cancers. This review consolidates the accumulating evidence on melatonin's multifaceted …
Published: March 11, 2024, midnight
GSK’s Jemperli combination recommended by NICE as first-line endometrial cancer treatment - PMLiVE
GSK’s Jemperli combination recommended by NICE as first-line endometrial cancer treatment PMLiVE
Published: March 5, 2024, 8 a.m.
Women need better care to avoid endometrial cancer development, study finds - University of Birmingham
Women need better care to avoid endometrial cancer development, study finds University of Birmingham
Published: March 1, 2024, 8 a.m.
Endocrine disruptors may increase the risk of endometrial cancer - ibsgranada.es
Endocrine disruptors may increase the risk of endometrial cancer ibsgranada.es
Published: Feb. 28, 2024, 8 a.m.
Loss of EIF4G2 mediates aggressiveness in distinct human endometrial cancer subpopulations with poor survival outcome in patients - Nature.com
Loss of EIF4G2 mediates aggressiveness in distinct human endometrial cancer subpopulations with poor survival outcome in patients Nature.com
Published: Feb. 22, 2024, 8 a.m.
Link copied to clipboard!